by Sue Robbins | Dec 1, 2020 | Migraine
How putting a program in place improved outcomes for employees with migraine Managing migraine at work can be hard for employees, but it also takes a toll on the company. That’s why Novartis, a global healthcare company based in Switzerland, launched a migraine...
by Sue Robbins | Nov 23, 2020 | Migraine
Therapy options for patients with migraines have expanded over the past couple of years, with several new drug classes specific to the disorder. Leading migraine experts discuss how they decide to choose one therapy over another. Treatment options for migraine have...
by Sue Robbins | Nov 22, 2020 | Migraine
In 2018 the FDA approved three new medications to treat migraine.1 These medications are known by the brand names Aimovig, Emgality, and Ajovy. All three medications are in a class called calcitonin gene-related peptide inhibitors (CGRPs). CGRPs developed to treat...
by Sue Robbins | Nov 17, 2020 | Migraine
Nearly 80% of people taking a new class of medication to prevent migraine say their migraine headaches are “better” since they started taking the drugs, according to a survey conducted by Eli Lilly. Calcitonin gene-related peptide (CGRP) inhibitors prevent migraines...
by Sue Robbins | Nov 12, 2020 | Migraine
Novartis announced positive results from a phase 4 study comparing treatment with erenumab (Aimovig), a calcitonin gene-related peptide (CGRP) receptor antagonist, to topiramate in patients with episodic and chronic migraine. The randomized, double-blind,...
